Last Updated on July 17, 2023 by The Health Master
The Delhi High Court in an interim order restrained generic drug maker Glenmark Pharmaceuticals from manufacturing, selling or advertising its asthma drug under the mark Indamet.
The drug which is allegedly identical or deceptively similar to Sun Pharma Laboratories’ registered mark for its anti-diabetes drug “Istamet XR CP”.
Sun Pharma and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing.
While Sun Pharma’s medicine Istamet sold in the form of tablets under the extensions – ISTAMEsT, ISTAMET XR, and ISTAMET XR CP – is a Schedule ‘G’ drug, Glenmark’s medicine under mark Indamet is a Schedule ‘H’ drug used for treatment of asthma.
Govt releases strategy document for Advancing the National Medical Devices Policy
Medical Store: Proposal to amend criteria for issuing Sale Licences
USFDA gives nod to this Nasal spray for Vitamin B12 deficiency
Govt has adopted a ‘Zero Tolerance’ policy on spurious medicines: HM
DTAB recommends amendment to Pack Size provisions for Tablets and Capsules
USFDA completes inspection of Granules India in two facilities
NPPA fixed Ceiling price of 2 scheduled formulations: June 2023
CDSCO orders transfer of 33 Deputy Drugs Controllers: List here
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
